Enveda’s third asset to the clinic with US FDA IND clearance: What it means for Inflammatory Bowel Disease

Enveda, a multi-asset clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, has announced that the US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ENV-6946.